PARIS (Agefi-Dow Jones)–The biotechnology company Valneva announced on Thursday that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended a marketing authorization (MA) in Europe of its candidate vaccine against Covid-19, VLA2001, for use as a primary vaccination in adults.
The CHMP concluded by consensus after a thorough assessment “that the data on the vaccine were strong and met European Union criteria for efficacy, safety and quality,” Valneva said in a statement. “The European Commission will examine the CHMP recommendation and a decision on the MA application for VLA2001 in Europe is expected soon”, continued the biotech.
If granted, VLA2001 would be the first Covid-19 vaccine to receive standard type marketing authorization in Europe. Once granted by the European Commission, the marketing authorization would be valid in all Member States of the European Union, as well as in Iceland, Liechtenstein and Norway.
Trading in Valneva shares has been suspended since Thursday morning at the company’s request. The suspension, effective from 9:00 a.m. on Thursday, will be in place until the publication of a new notice, Euronext said. On Wednesday evening, Valneva shares closed down 1% to 11.90 euros.
In addition, the general meeting of shareholders of Valneva began at 2:00 p.m. on Thursday.
-Dimitri Delmond, Agefi-Dow Jones; +33 (0)1 41 27 47 31; [email protected] ed: VLV
Agefi-Dow Jones The financial newswire
Dow Jones Newswires
June 23, 2022 09:37 ET (13:37 GMT)